IXICO plc (IXI) Price & Analysis

Compare

15 Followers

IXI Stock Chart & Stats

11.75p

-0.75p(-6.25%)

At close: Jan 08 4:00 PM EST

11.75p

-0.75p(-6.25%)

Day’s Range― - ―

52-Week Range7.00p - 15.00p

Previous CloseN/A

Volume22.18K

Average Volume (3M)123.87K

Market Cap

£8.22M

Enterprise Value3.71M

Total Cash (Recent Filing)£3.54M

Total Debt (Recent Filing)£179.00K

Price to Earnings (P/E)―

Beta1.07

Next Earnings

May 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding92,668,594

10 Day Avg. Volume82,815

30 Day Avg. Volume123,868

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)1.01

Price to Sales (P/S)1.81

P/FCF Ratio-12.69

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Order Book GrowthA materially larger order book provides durable revenue visibility across multiple upcoming quarters, underpinning the company’s projected 15% revenue growth. Strong forward bookings reduce quarter-to-quarter volatility and support scaling of fixed-cost platforms toward long-term profitability.

CNS Niche & AI Biomarker PlatformSpecialization in neurodegenerative diseases and an AI-driven biomarker analytics platform are structural competitive advantages: they create high switching costs, align with growing R&D demand in CNS, and enable differentiated service offerings that can sustain margin improvement as volumes scale.

Conservative Balance SheetA solid net asset base and cash buffer, combined with low reported leverage, give IXICO runway to invest in platform and partnerships without immediate refinancing pressure. This financial resilience supports multi-quarter execution of strategic initiatives and partnership expansion.

Bears Say

Persistent EBITDA LossOngoing negative EBITDA constrains internal reinvestment and heightens reliance on improving revenue mix to reach breakeven. Even with a 20% reduction in loss, persistent operating deficits limit free-cash generation and increase execution risk before sustainable profitability is achieved.

Negative Operating Cash FlowNegative and volatile cash flows indicate difficulty converting revenue and earnings into cash, weakening the company’s ability to self-fund growth or absorb shocks. This structural cash-generation weakness raises dependence on external funding or slower growth to reach a stable cash-positive position.

Revenue And Margin PressureA multi-year revenue decline with recent margin compression suggests persistent demand or pricing challenges and cost pressure. Even with recent 13% recovery, the firm needs sustained top-line expansion and operational leverage to restore historical margins and achieve the stated breakeven revenue threshold.

IXICO plc News

IXICO Wins £1.5m Contract Extension on Phase 2 Huntington’s Trial

An announcement from IXICO plc ( ($GB:IXI) ) is now available. IXICO plc, a London-listed neuroscience imaging and...

9d ago

IXICO Wins £1.5m Extension on Global Huntington’s Disease Trial

IXICO plc ( ($GB:IXI) ) has shared an update. IXICO plc, a London-headquartered imaging Contract Research Organisation focused...

9d ago

IXICO hires US-based Chief Commercial Officer to drive growth and expand neuroimaging business

IXICO plc ( ($GB:IXI) ) has provided an announcement. IXICO has appointed Tanya Voloshen as its new Chief...

16d ago

IXICO Secures Strong Shareholder Backing as All AGM Resolutions Pass

An announcement from IXICO plc ( ($GB:IXI) ) is now available. IXICO plc reported that all resolutions at...

29d ago

IXICO plc Earnings Call: Positive Growth and Strategic Focus

IXICO plc (($GB:IXI)) has held its Q4 earnings call. Read on for the main highlights of the call....

2M ago

IXICO plc Issues Share Options to Leadership Team

The latest announcement is out from IXICO plc ( ($GB:IXI) ). IXICO plc has announced the issuance of...

2M ago

IXICO plc Reports Strong Financial Growth and Strategic Expansion

IXICO plc ( ($GB:IXI) ) has shared an announcement. IXICO plc reported a strong financial performance for the...

2M ago

IXICO plc Reports Strong Financial Growth and Strategic Expansion

IXICO plc ( ($GB:IXI) ) has provided an update. IXICO plc reported strong financial results for the year...

2M ago

IXICO Enhances Advisory Board with Alzheimer’s and Vascular Experts

IXICO plc ( ($GB:IXI) ) has shared an announcement. IXICO plc has announced the appointment of two renowned...

3M ago

IXICO plc to Announce 2025 Full Year Results and Host Investor Presentation

An update from IXICO plc ( ($GB:IXI) ) is now available. IXICO plc has announced it will release...

3M ago

IXI FAQ

What was IXICO PLC’s price range in the past 12 months?

IXICO PLC lowest share price was 7.00p and its highest was 15.00p in the past 12 months.

What is IXICO PLC’s market cap?

IXICO PLC’s market cap is £8.22M.

When is IXICO PLC’s upcoming earnings report date?

IXICO PLC’s upcoming earnings report date is May 26, 2026 which is in 94 days.

How were IXICO PLC’s earnings last quarter?

IXICO PLC released its earnings results on Dec 09, 2025. The company reported -0.008p earnings per share for the quarter, missing the consensus estimate of N/A by -0.008p.

Is IXICO PLC overvalued?

According to Wall Street analysts IXICO PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does IXICO PLC pay dividends?

IXICO PLC does not currently pay dividends.

What is IXICO PLC’s EPS estimate?

IXICO PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does IXICO PLC have?

IXICO PLC has 92,668,594 shares outstanding.

What happened to IXICO PLC’s price movement after its last earnings report?

IXICO PLC reported an EPS of -0.008p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.953%.

Which hedge fund is a major shareholder of IXICO PLC?

Currently, no hedge funds are holding shares in GB:IXI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

IXICO PLC

IXICO plc (IXI) is a leading analytics and technology company that specializes in the provision of imaging and data analytics services in the healthcare sector, particularly for clinical trials and neurological diseases. The company operates primarily in the pharmaceutical and biotechnology industries, offering core services that include advanced imaging analysis, data management, and the interpretation of clinical data to support drug development and regulatory submissions.